ELIXIR MD™, a global leader in photobiomodulation technology, has achieved a major milestone in the field of plastic surgery. The company announced its revolutionary technology, EPBM™ has received FDA 510(k) clearance for use in general and plastic surgery procedures. This makes ELIXIR MD™ the first and only company to receive such clearance for an LED light therapy device in the plastic surgery industry.
The FDA clearance is a significant achievement for ELIXIR MD™ and a testament to the safety and effectiveness of its EPBM™ technology. This clearance allows plastic surgeons to use ELIXIR MD™ device in a variety of procedures. The EPBM™ technology utilizes specific wavelengths of light to stimulate cellular activity, promoting healing and reducing inflammation, pain, and scarring.
“ELIXIR MD™ is committed to investing in R&D to provide plastic surgeons with the advancements they need to deliver the highest quality of care and achieve the fastest post-surgery results,” said Ewan Yassen, CEO of ELIXIR MD™. “The new indication for soft tissue coagulation for LED light therapy in plastic surgery enhances the product’s intended use, helping practitioners expand their patient base.”
Since its inception, ELIXIR MD™ has been gaining widespread global brand awareness, with more than 70 plastic surgeons using the system worldwide. The ELIXIR MD™ brand is poised to become the new standard in plastic surgery for post-op recovery solutions.
